Company UpdateNewspaper Publication
HealthcarePharmaceuticals & BiotechnologyPharmaceuticals
Pharmaids Pharmaceuticals Ltd
Showing the latest 10 filings. Sign in to filter or browse the full history.
10 of 42 filings·Updated 19 Aug 2026
Showing 10 of 42 filings.
19 Aug 20261 filing
18 Aug 20261 filing
AGM/EGMAGM
Pharmaids Pharma to hold 37th AGM on 11 September 2026 via VC/OAVM with ED reappointment and RPT approvals
AGM Details
- Date/time/mode: 11 September 2026, 12:00 IST; VC/OAVM.
- Cut-off for e-voting: 4 September 2026; voting window: 8–10 September 2026.
Resolutions to Vote On
- Adoption of standalone and consolidated financial statements for FY2025-26.
- Re-appointment of Ms Mini Manikantan as Executive Director (retire by rotation).
- Approval of material related party transactions for the Company.
- Approval of material related party transactions for subsidiaries.
Dividend
- No final dividend proposed for FY2025-26.
Governance & Auditors
- Statutory Auditor: reappointed M/s PPKG & Co for five years (2023–28).
- Internal Auditor FY2025-26: TN Raghavendra; FY2026-27: M/s V Mahendra & Associates.
- Secretarial Auditor: Kashinath Sahu & Co.
Key Director/KMP Changes
- Independent Director Yogananda Moolemath appointed Jan 1, 2026.
- Mopperthy Sudheer ceased Independent Director Jan 5, 2026.
- Chairman shifted: Pattamadai Vijay appointed Chairman Dec 5, 2025; Shankarappa Vinaya Babu became Vice-Chairman.
- CEO/KMP changes: Dr. S Prasad resigned Aug 7, 2025; Sidde Gowda resigned Dec 10, 2025; Jagadeesh M N resigned Jun 25, 2026.
- Re-appointment: Ms Mini Manikantan offered for re-appointment as Executive Director.
Material Related Party Transactions
- RPT approvals cover transactions with related parties; details in Annexure I (Company) and Annexure II (Subsidiaries).
- Aggregate RPT limits: Company up to Rs 66 cr; Subsidiaries up to Rs 130 cr.
Subsidiaries / Other Governance Notes
- Anugraha Chemicals ceased to be a material subsidiary in Sept 2025.
- Siri Labvivo Diet Private Limited ceased as step-down subsidiary Mar 2026.
14 Aug 20261 filing
Company UpdateNewspaper Publication
Newspaper publication of unaudited financial results (standalone & consolidated) for the quarter ended June 30, 2026
12 Aug 20261 filing
ResultFinancial Results
Pharmaids Pharmaceuticals approves unaudited standalone and consolidated results for quarter ended June 30, 2026
Board approvals
- Board approves unaudited standalone and consolidated results for quarter ended June 30, 2026.
- Limited Review Report by M/s PPKG & Co enclosed with results.
- Advertisement planned with QR code and webpage link for full results and report.
- Notice for 37th AGM to be held via VC/OAVM; details to follow.
- Board meeting duration: 04:57 PM to 06:15 PM.
7 Jul 20261 filing
Company UpdateCertificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Certificate confirms dematerialisation compliance; depositories updated as registered owners within 15 days
Dematerialisation status and depository updates
- Securities received for dematerialisation mutilated and cancelled after due verification.
- Depositories NSDL and CDSL updated as registered owner within 15 days.
- Details of the securities furnished to the stock exchanges.
- Certificate confirms compliance with dematerialisation for the quarter ended 30 June 2026.
- RTA: Venture Capital and Corporate Investments Private Limited confirms processing.
30 Jun 20261 filing
Company UpdateChange in Management
Pharmaids appoints M/s V Mahendra & Associates as Internal Auditors for FY2026-27
Internal Auditor Appointment
- Board approved appointment of M/s V Mahendra & Associates as Internal Auditors for FY2026-27 on 30 June 2026.
- Reason: to carry out Internal Audit for the financial year 2026-27.
- Profile: Chartered Accountant firm with over 23 years of experience.
13 Jun 20261 filing
Company UpdateGeneral
Announcement under Regulation 30 of SEBI (LODR) Regulations, 2015 - Providing corporate guarantee to subsidiary, Adita Bio Sys Private Limited
31 May 20261 filing
Company UpdateNewspaper Publication
Newspaper publication of Audited Financial Results (Standalone and Consolidated) for the quarter and year ended March 31, 2026
24 Apr 20261 filing
Company UpdateNewspaper Publication
Newspaper publication regarding the Special Window open for Re-Lodgement of transfer deeds.
27 Mar 20261 filing
Company UpdateGeneral
Sale of entire shareholding held by Adita Bio Sys Private Limited (material subsidiary of the Company) in Siri Labvivo Diet Private Limited, a step-down subsidiary, resulting in cessation ....
Showing 10 of 42 filings